TABLE 1.
Clinical features of CN group with amyloid-negative, CN, MCI, and AD groups with amyloid-positive.
| CN A– | CN A+ | MCI A+ | AD A+ | |
| Subjects | 96 | 54 | 195 | 85 |
| Age (mean ± sd) | 73.9 ± 5.3 | 75.8 ± 6.0 | 72.7 ± 7.1 | 74.2 ± 8.4 |
| Gender | ||||
| Male | 58 (60.4%) | 23 (42.6%) | 114 (58.5%) | 43 (50.6%) |
| Female | 38 (39.6%) | 31 (57.4%) | 81 (41.5%) | 42 (49.4%) |
| Years of education (mean ± sd) | 16.4 ± 2.7 | 16.0 ± 2.0 | 15.9 ± 2.9 | 15.0 ± 2.6 |
| APOE allele ε 4 carrier | 10 (10.4%) | 25 (46.3%) | 131 (67.2%) | 62 (72.9%) |
| Baseline ADAS13 score (mean ± sd) | 9.23 ± 4.14 | 9.47 ± 3.84 | 18.12 ± 6.73 | 30.52 ± 7.53 |
| Baseline MMSE score (mean ± sd) | 29.1 ± 1.2 | 29.0 ± 1.1 | 27.4 ± 1.8 | 23.3 ± 1.8 |
| Mean number of visits for ADAS13 (mean ± sd) | 5.51 ± 1.92 | 5.57 ± 1.96 | 4.74 ± 1.94 | 2.64 ± 0.65 |
| Mean follow-up years for ADAS13 (mean ± sd) | 5.67 ± 2.32 | 5.48 ± 2.14 | 4.00 ± 2.21 | 1.67 ± 0.66 |
| Mean number of visits for MMSE (mean ± sd) | 5.52 ± 1.91 | 5.61 ± 1.96 | 4.80 ± 1.96 | 2.72 ± 0.68 |
| Mean follow-up years for MMSE (mean ± sd) | 5.65 ± 2.32 | 5.52 ± 2.15 | 4.06 ± 2.21 | 1.73 ± 0.68 |